Predictive value of expression of ERCC 1 and GST-p for 5-fluorouracil/ oxaliplatin chemotherapy in advanced colorectal cancer

Hepato-Gastroenterology

Volumn 59, Issue 113, 2012, Pages 130-133

  Noda, Eiji ^a   Maeda, Kiyoshi ^a   Inoue, Toru ^a   Fukunaga, Shinya ^a   Nagahara, Hisashi ^a   Shibutani, Masatsune ^a   Amano, Ryosuke ^a   Nakata, Bunzo ^a   Tanaka, Hiroaki ^a   Muguruma, Kazuya ^a   Yamada, Nobuya ^a   Yashiro, Masakazu ^a   Ohira, Masaichi ^a   Ishikawa, Tetsuro ^a   Hirakawa, Kosei ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Colorectal cancer; ERCC 1; FOLFOX; GST p; Immuno histochemistry; TS

Indexed keywords

EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FLUOROURACIL; GLUTATHIONE TRANSFERASE ALPHA; OXALIPLATIN; THYMIDYLATE SYNTHASE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; COLORECTAL CANCER; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; PREDICTIVE VALUE; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT RESPONSE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DNA-BINDING PROTEINS; ENDONUCLEASES; FEMALE; FLUOROURACIL; GLUTATHIONE S-TRANSFERASE PI; HUMANS; IMMUNOHISTOCHEMISTRY; JAPAN; LEUCOVORIN; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ORGANOPLATINUM COMPOUNDS; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; THYMIDYLATE SYNTHASE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84858164003     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: 10.5754/hge11022     Document Type: Article

References (30)

1. De Gramont A, Figer A, Seymour M, et al.: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18:2938-47. (Pubitemid 30644117)
2. Johnson NP, Hoeschele JD, Rahn RO: Kinetic analysis of the in vitro binding of radioactive cis- and trans-dichlorodiammine-platinum (II) to DNA. Chem Biol Interact 1980; 30:151-69.
3. de Laat WL, Jaspers NG, Hoeijmakers JH: Molecular mechanism of nucleotide excision repair. Genes Dev 1999; 13:768-85. (Pubitemid 29169836)
4. Rosell R, Mendez P, Isla D, Taron M: Platinum resistance related to a functional NER pathway. J Thorac Oncol 2007; 2:1063-6. (Pubitemid 350307897)
5. Kang S, Ju W, Kim JW, et al.: Association between excision repair cross-complementation group 1 polymorphism and clinical outcome of platinum-based chemotherapy in patients with epithelial ovarian cancer. Exp Mol Med 2006; 38:320-4. (Pubitemid 44033245)
6. Dabholkar M, Bostick-Bruton F, Weber C, Bohr VA, Egwuagu C, Reed E: ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients. J Natl Cancer Inst 1992; 84:1512-7.
7. Shirota Y, Stoehlmacher J, Brabender J, et al.: ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 2001; 19:4298-304. (Pubitemid 33096777)
8. Metzger R, Leichman CG, Danenberg KD, et al.: ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol 1998; 16:309-16. (Pubitemid 28041614)
9. Lord RV, Brabender J, Gandara D, et al.: Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 2002; 8:2286-91. (Pubitemid 34753602)
10. Moscow JA, Fairchild CR, Madden MJ, et al.: Expression of anionic glutathione-S-transferase and P-glycoprotein genes in human tissues and tumors. Cancer Res 1989; 49:1422-8. (Pubitemid 19088676)
11. Goto S, Iida T, Cho S, Oka M, Kohno S, Kondo T: Overexpression of glutathione S-transferase pi enhances the adduct formation of cisplatin with glutathione in human cancer cells. Free Radic Res 1999; 31:549-58.
12. Cascinu S, Aschele C, Barni S, et al.: Thymidylate synthase protein expression in advanced colon cancer: correlation with the site of metastasis and the clinical response to leucovorin-modulated bolus 5-fluorouracil. Clin Cancer Res 1999; 5:1996-9. (Pubitemid 29399249)
13. Johnston PG, Lenz HJ, Leichman CG, et al.: Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 1995; 55:1407-12.
14. Leichman CG, Lenz HJ, Leichman L, et al.: Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J Clin Oncol 1997; 15:3223-9. (Pubitemid 27419335)
15. Leichman CG: Thymidylate synthase as a predictor of response. Oncology (Williston Park) 1998; 12:43-7.
16. Van Duin M, de Wit J, Odijk H, et al.: Molecular characterization of the human excision repair gene ERCC-1: cDNA cloning and amino acid homology with the yeast DNA repair gene RAD10. Cell 1986; 44:913-23. (Pubitemid 16045337)
17. Kwon HC, Roh MS, Oh SY, et al.: Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/ oxaliplatin chemotherapy in advanced gastric cancer. Ann Oncol 2007; 18:504-9. (Pubitemid 46359630)
18. Stoehlmacher J, Park DJ, Zhang W, et al.: Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. J Natl Cancer Inst 2002; 94:936-42. (Pubitemid 34778092)
19. Nishimura T, Newkirk K, Sessions RB, et al.: Immunohistochemical staining for glutathione S-transferase predicts response to platinum-based chemotherapy in head and neck cancer. Clin Cancer Res 1996; 2:1859-65. (Pubitemid 26384153)
20. Shiga H, Heath EI, Rasmussen AA, et al.: Prognostic value of p53, glutathione S-transferase pi, and thymidylate synthase for neoadjuvant cisplatin-based chemotherapy in head and neck cancer. Clin Cancer Res 1999; 5:4097-104. (Pubitemid 30013791)
21. Noda E, Maeda K, Inoue T, et al.: Expression of genes for 5-FU-metabolizing enzymes and response to irinotecan plus 5-FU-leucovorin in colorectal cancer. Anticancer Res 2006; 26:4653-8. (Pubitemid 46032095)
22. Nordlinger B, Van Cutsem E, Gruenberger T, et al.: Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel. Ann Oncol 2009; 20:985-92.
23. Tournigand C, Andre T, Achille E, et al.: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22:229-37. (Pubitemid 41095086)
24. Folprecht G, Grothey A, Alberts S, Raab HR, Kohne CH: Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol 2005; 16:1311-9. (Pubitemid 41158476)
25. Falcone A, Ricci S, Brunetti I, et al.: Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest J Clin Oncol 2007; 25:1670-6. (Pubitemid 46797946)
26. Masi G, Loupakis F, Pollina L, et al.: Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases. Ann Surg 2009; 249:420-5.
27. Saltz LB, Clarke S, Diaz-Rubio E, et al.: Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26:2013-9.
28. Van Cutsem E, Kohne CH, Hitre E, et al.: Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360:1408-17.
29. Van Cutsem E, Rivera F, Berry S, et al.: Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol 2009; 20:1842-7.
30. Adam R, Wicherts DA, de Haas RJ, et al.: Patients with initially unresectable colorectal liver metastases: is there a possibility of cure? J Clin Oncol 2009; 27:1829-35.